Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17135158 | METHOD AND COMPOUNDS FOR TREATING PERIPHERAL NEUROPATHY | December 2020 | November 2022 | Allow | 23 | 1 | 1 | Yes | No |
| 17108947 | ENCAPSULATED ANTIMICROBIALS AND RELATED METHODS OF TREATMENT | December 2020 | February 2023 | Allow | 26 | 2 | 1 | No | No |
| 17059770 | CORE-SHELL POLYMER NANOPARTICLE | November 2020 | May 2023 | Allow | 29 | 1 | 1 | No | No |
| 17104238 | Effervescent Drug Formulations | November 2020 | April 2023 | Abandon | 29 | 3 | 0 | Yes | No |
| 17247045 | Carbohydrate-Modified Particles and Particulate Formulations for Modulating an Immune Response | November 2020 | November 2022 | Abandon | 23 | 2 | 0 | Yes | No |
| 17057415 | BIOMIMETIC VESICLES AND USES THEREOF | November 2020 | May 2022 | Allow | 18 | 0 | 1 | No | No |
| 16950359 | CHITOSAN CONTAINING COMPOSITIONS AND METHODS RELATING TO SAME | November 2020 | October 2023 | Abandon | 35 | 2 | 1 | No | No |
| 17054539 | Endolysins Active Against Bacillus Bacteria, Pharmaceutical Compositions, and Methods Relating Thereto | November 2020 | September 2023 | Allow | 34 | 0 | 1 | No | No |
| 17093302 | FORMULATION OF GLUCOSINOLATES AND MYROSINASE | November 2020 | July 2022 | Abandon | 20 | 1 | 0 | No | No |
| 17092184 | COMPOSITIONS AND METHODS FOR PROTECTING AGAINST AIRBORNE PATHOGENS AND IRRITANTS | November 2020 | January 2024 | Abandon | 38 | 4 | 1 | No | No |
| 17050803 | LONG LASTING COSMETIC COMPOSITIONS | October 2020 | March 2024 | Allow | 41 | 1 | 1 | No | No |
| 17049152 | CATIONIC AMPHIPHILIC POLYMERS FOR CODELIVERY OF HYDROPHOBIC AGENTS AND NUCLEIC ACIDS | October 2020 | July 2023 | Allow | 33 | 0 | 0 | No | No |
| 17060593 | CHLOROGENIC ACID-CONTAINING COMPOSITION FOR NASAL ADMINISTRATION | October 2020 | October 2022 | Allow | 25 | 1 | 1 | No | No |
| 17042887 | COMBINATION OF POLYETHYLENE GLYCOL AND RAPAMYCIN AND USE THEREOF | September 2020 | January 2023 | Abandon | 27 | 3 | 0 | No | No |
| 17041592 | Multidentate Phenanthridine-Containing Ligand Frameworks and Their Planar Monofunctional Platinum Complexes for Cancer Treatment | September 2020 | December 2021 | Allow | 15 | 0 | 0 | No | No |
| 17041108 | TOPICAL AND TRANSDERMAL DELIVERY OF AN IRON CHELATOR TO PREVENT AND TREAT CHRONIC WOUNDS | September 2020 | October 2022 | Abandon | 25 | 1 | 1 | No | No |
| 17030286 | Nanoencapsulated Combination Drug Formulations | September 2020 | January 2023 | Allow | 28 | 2 | 1 | Yes | No |
| 17040916 | AN IONIC LIQUID-BASED NANOEMULSION FORMULATION FOR THE EFFICIENT DELIVERY OF HYDROPHILIC AND HYDROPHOBIC THERAPEUTIC AGENTS | September 2020 | May 2022 | Allow | 19 | 0 | 1 | No | No |
| 16981745 | LONG-ACTING INJECTABLE FORMULATIONS AND CRYSTALLINE FORMS OF BUPRENORPHINE DERIVATIVES | September 2020 | February 2022 | Allow | 17 | 0 | 1 | No | No |
| 17020729 | WATER SOLUBLE COMPOSITIONS AND METHODS OF MAKING THE SAME | September 2020 | March 2022 | Allow | 18 | 0 | 1 | No | No |
| 17016953 | IMPLANTABLE THERAPEUTIC DEVICE | September 2020 | December 2023 | Abandon | 39 | 0 | 1 | No | No |
| 16978595 | NATURAL COMBINATION PRODUCTS AND METHODS FOR REGULATION OF KIDNEY AND EXCRETORY SYSTEM FUNCTION | September 2020 | April 2023 | Allow | 31 | 3 | 0 | No | No |
| 17009586 | SELF-EMULSIFYING FORMULATIONS OF DIM-RELATED INDOLES | September 2020 | January 2022 | Allow | 17 | 1 | 0 | Yes | No |
| 17003699 | THERAPEUTIC DENDRIMER | August 2020 | May 2021 | Allow | 8 | 1 | 1 | Yes | No |
| 16967199 | OXIME GROUP-CONTAINING CONDENSED HETEROCYCLIC COMPOUND OR SALT THEREOF, AGRICULTURAL AND HORTICULTURAL INSECTICIDE COMPRISING THE COMPOUND, AND METHOD FOR USING THE INSECTICIDE | August 2020 | July 2023 | Allow | 36 | 0 | 0 | No | No |
| 16942277 | MICROBICIDAL COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | July 2020 | January 2023 | Abandon | 29 | 2 | 1 | No | No |
| 16940231 | Bi-Functional Co-Polymer Use for Ophthalmic and Other Topical and Local Applications | July 2020 | July 2021 | Allow | 12 | 1 | 0 | No | No |
| 16962602 | NEW ALK INHIBITOR SENOLYTIC DRUGS | July 2020 | January 2023 | Abandon | 30 | 1 | 1 | No | No |
| 16960874 | Formulation for the Treatment of Polymorphisms in Methyl Metabolizing Genes and Methods of Treatment Thereof | July 2020 | November 2022 | Abandon | 28 | 2 | 0 | No | No |
| 16960054 | NOVEL COMPOSITE BIOLOGICAL AGENT BASED ON POROUS FRAME MATERIALS | July 2020 | June 2023 | Allow | 35 | 3 | 2 | No | No |
| 16915017 | OCULAR IMPLANT MADE BY A DOUBLE EXTRUSION PROCES | June 2020 | April 2022 | Allow | 21 | 1 | 0 | No | No |
| 16911334 | COMPOSITIONS COMPRISING CANNABIS SATIVA OIL AND USES THEREOF | June 2020 | July 2022 | Abandon | 25 | 2 | 0 | No | No |
| 16909231 | EXTENDED RELEASE LIQUID COMPOSITIONS OF METFORMIN | June 2020 | August 2022 | Allow | 25 | 3 | 0 | No | No |
| 16955336 | OCULAR DRUG DELIVERY | June 2020 | May 2023 | Allow | 35 | 3 | 0 | No | No |
| 16946219 | SYSTEM, METHODS AND KITS FOR DIAGNOSIS AND TREATMENT OF FEMALE PATTERN HAIR LOSS | June 2020 | October 2023 | Abandon | 40 | 4 | 1 | No | No |
| 16897966 | NICOTINE LOZENGE | June 2020 | May 2021 | Allow | 11 | 0 | 0 | No | No |
| 16897917 | COMPOSITIONS AND METHODS OF TREATING FUNGAL INFECTIONS OF THE NAILS | June 2020 | August 2021 | Allow | 14 | 0 | 0 | No | No |
| 16888348 | BIOERODIBLE CROSS-LINKED HYDROGEL IMPLANTS AND RELATED METHODS OF USE | May 2020 | December 2023 | Abandon | 42 | 3 | 1 | No | No |
| 16767370 | SOFT CONTACT LENS TREATMENT SOLUTION | May 2020 | April 2023 | Allow | 35 | 1 | 1 | No | No |
| 16883917 | Biodegradable Microcapsules Containing Filling Material | May 2020 | November 2021 | Abandon | 18 | 1 | 0 | No | No |
| 16882979 | PHARMACEUTICAL COMPOSITION | May 2020 | March 2022 | Allow | 21 | 3 | 0 | Yes | No |
| 16883016 | PHARMACEUTICAL COMPOSITION | May 2020 | May 2021 | Allow | 12 | 1 | 0 | No | No |
| 16882429 | TOPICAL COMPOSITIONS, PROCESS OF LARGE-SCALE MANUFACTURE, AND METHOD OF USE | May 2020 | March 2022 | Allow | 22 | 1 | 1 | No | No |
| 16766326 | CATHETER LOCK SOLUTION COMPRISING SODIUM CITRATE AND BENZYL ALCOHOL | May 2020 | April 2023 | Allow | 35 | 1 | 1 | No | No |
| 16763372 | EMULSIONS FOR TREATING MUCOUS MEMBRANE INFECTIONS | May 2020 | April 2023 | Allow | 35 | 2 | 1 | Yes | Yes |
| 16762881 | A COMBINATION THERAPY WITH APATINIB FOR THE TREATMENT OF CANCER | May 2020 | June 2024 | Abandon | 49 | 6 | 0 | Yes | No |
| 16762544 | OCULAR APPLICATIONS OF SILK-BASED PRODUCTS | May 2020 | September 2022 | Abandon | 29 | 2 | 1 | No | No |
| 16870643 | COMPOSITIONS AND METHODS FOR INVASIVE AND NON-INVASIVE PROCEDURAL SKINCARE | May 2020 | April 2022 | Allow | 23 | 3 | 0 | No | No |
| 16869081 | SYSTEM AND METHOD FOR ALLERGEN-SPECIFIC EPICUTANEOUS IMMUNOTHERAPY | May 2020 | November 2022 | Allow | 30 | 1 | 1 | Yes | No |
| 16856693 | TERPENE-CONTAINING COMPOSITIONS AND METHODS OF MAKING AND USING THEM | April 2020 | August 2023 | Abandon | 39 | 4 | 0 | No | No |
| 16851862 | THERAPEUTIC AGENT FOR SKIN WOUND OR ROUGH SKIN | April 2020 | March 2021 | Allow | 11 | 0 | 0 | No | No |
| 16753245 | NONVIRAL GENE TRANSFER TO THE SUPRACHOROIDAL SPACE | April 2020 | September 2023 | Allow | 41 | 3 | 1 | Yes | No |
| 16822412 | LISINOPRIL FORMULATIONS | March 2020 | December 2020 | Allow | 9 | 1 | 0 | Yes | No |
| 16646466 | Polymer and dosage form with sustained release properties and resistance against the influence of ethanol | March 2020 | November 2021 | Allow | 20 | 0 | 1 | No | No |
| 16646063 | HYDROPHILIC MEDICAL DEVICE WITH REMOVABLE MOISTURE CONTROL/BARRIER LAYER | March 2020 | September 2022 | Allow | 30 | 1 | 1 | No | No |
| 16813026 | Amphiphile-Polymer Particles | March 2020 | February 2023 | Abandon | 35 | 2 | 1 | No | No |
| 16643564 | CARRIER COMPOSITION FOR EYE DROPS AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | March 2020 | June 2021 | Allow | 15 | 0 | 0 | No | No |
| 16805080 | STABILIZED COATED BUTYRATE FOR COLON RELEASE | February 2020 | January 2022 | Abandon | 23 | 1 | 1 | No | No |
| 16637092 | COMPOSITIONS AND METHODS FOR INHIBITING HIV-1 REVERSE TRANSCRIPTASE | February 2020 | September 2021 | Abandon | 20 | 0 | 1 | No | No |
| 16636908 | DISINTEGRIN VARIANTS AND USES THEREOF | February 2020 | October 2021 | Allow | 20 | 0 | 0 | No | No |
| 16751288 | PULSE DOSING REGIMEN AND METHODS OF TREATMENT | January 2020 | October 2021 | Allow | 21 | 1 | 0 | No | No |
| 16632459 | TISSUE FILLER COMPOSITIONS FOR PHOTO-BIOMODULATION AND METHODS FOR ACHIEVING SAME | January 2020 | January 2023 | Allow | 36 | 1 | 0 | No | No |
| 16631436 | MICROPARTICLE FORMULATIONS FOR DELIVERY OF ACTIVE AGENTS | January 2020 | June 2022 | Abandon | 29 | 1 | 1 | No | No |
| 16740576 | DUAL-FUNCTION STARCH-BASED COMPOSITE NANOPARTICLES AS WELL AS PREPARATION METHOD AND APPLICATION THEREOF | January 2020 | November 2021 | Allow | 22 | 0 | 1 | No | No |
| 16739180 | Modified Polyvinylchloride Surface with Antibacterial and Antifouling Functions | January 2020 | January 2023 | Abandon | 36 | 0 | 1 | No | No |
| 16737371 | POLYMER BASED TRANSPLANT PRESERVATION SOLUTION | January 2020 | February 2022 | Allow | 25 | 2 | 0 | Yes | No |
| 16628232 | DRUG FOR RETINAL DEGENERATIVE DISEASE ASSOCIATED WITH PHOTORECEPTOR DEGENERATION | January 2020 | November 2023 | Allow | 47 | 3 | 1 | No | No |
| 16726750 | MEDICAL DEVICE COATING WITH A BIOCOMPATIBLE LAYER | December 2019 | October 2021 | Allow | 22 | 1 | 1 | Yes | No |
| 16626084 | PHARMACEUTICAL PREPARATION AND PREPARATION METHOD THEREFOR | December 2019 | July 2022 | Allow | 31 | 2 | 1 | No | No |
| 16713232 | ENHANCEMENT OF THE EFFICACY OF THERAPEUTIC PROTEINS | December 2019 | November 2021 | Abandon | 23 | 0 | 1 | No | No |
| 16622286 | PROBIOTICS-DELIVERING HYDROGEL FORMULATION FOR PROTECTING PROBIOTICS IN ACIDIC ENVIRONMENT AND COMPOSITION FOR DELIVERING PROBIOTICS COMPRISING SAME | December 2019 | September 2022 | Allow | 33 | 4 | 1 | No | No |
| 16705422 | SUBLINGUAL AND BUCCAL FILM COMPOSITIONS | December 2019 | August 2021 | Abandon | 20 | 1 | 0 | No | No |
| 16705893 | Pharmaceutical Composition for Oral Delivery of Hydrophobic Small Molecule Drug and Hydrophilic Small Molecule Drug Concurrently | December 2019 | January 2022 | Abandon | 26 | 2 | 0 | No | No |
| 16682171 | NUTRITIONAL SUPPLEMENT FOR IMPROVED CALCIUM ABSORPTION | November 2019 | October 2021 | Abandon | 23 | 2 | 0 | Yes | No |
| 16681261 | TRIPULSE RELEASE STIMULANT FORMULATIONS | November 2019 | October 2022 | Abandon | 35 | 2 | 1 | Yes | No |
| 16611078 | MEDICAL DEVICE | November 2019 | November 2023 | Allow | 48 | 2 | 1 | Yes | No |
| 16670197 | MICRONIZED PLACENTAL TISSUE COMPOSITIONS WITH OPTIONAL SEALANT AND METHODS OF MAKING AND USING THE SAME | October 2019 | June 2024 | Abandon | 56 | 6 | 1 | Yes | No |
| 16657887 | SYSTEMS FOR PEST ELIMINATION, SUPPRESSION OR CONTROL | October 2019 | May 2022 | Abandon | 31 | 2 | 1 | No | No |
| 16597237 | PHARMACEUTICAL COMPOSITION | October 2019 | May 2021 | Abandon | 19 | 1 | 0 | No | No |
| 16595425 | PHARMACEUTICAL COMPOSITION AND METHODS | October 2019 | August 2024 | Abandon | 59 | 6 | 0 | No | Yes |
| 16592643 | SILICONE-CONTAINING ACRYLIC POLYMERS FOR TRANSDERMAL DRUG DELIVERY COMPOSITIONS | October 2019 | March 2022 | Allow | 30 | 2 | 0 | No | Yes |
| 16588761 | SUBCUTANEOUS DELIVERY OF POLYMER CONJUGATES OF THERAPEUTICS AGENTS | September 2019 | December 2021 | Allow | 26 | 0 | 1 | No | No |
| 16582993 | PHARMACEUTICAL COMPOSITION | September 2019 | September 2021 | Allow | 24 | 2 | 0 | Yes | No |
| 16582973 | PHARMACEUTICAL COMPOSITION | September 2019 | May 2021 | Allow | 20 | 1 | 0 | No | No |
| 16565790 | Base Composition for Tape Agent | September 2019 | June 2021 | Abandon | 21 | 1 | 0 | No | No |
| 16563996 | PHARMACEUTICAL COMPOSITION FOR TREATING LEUKEMIA AND METHOD FOR PREPARING THE SAME | September 2019 | January 2022 | Abandon | 28 | 2 | 1 | No | No |
| 16564904 | LISINOPRIL FORMULATIONS | September 2019 | May 2021 | Abandon | 21 | 1 | 0 | No | No |
| 16563678 | Microabrasive Compositions Containing O�idS | September 2019 | June 2021 | Allow | 22 | 1 | 1 | No | No |
| 16554717 | COSMETIC AND HOUSEHOLD CARE COMPOSITIONS | August 2019 | March 2021 | Allow | 19 | 1 | 0 | Yes | No |
| 16531707 | Transmucosal Administration System for a Pharmaceutical Drug | August 2019 | October 2021 | Abandon | 27 | 1 | 0 | No | No |
| 16528007 | PHARMACEUTICAL CYCLOSPORIN COMPOSITIONS | July 2019 | April 2021 | Abandon | 21 | 1 | 0 | No | No |
| 16482177 | TOPICAL COMPOSITION | July 2019 | April 2023 | Allow | 45 | 2 | 1 | Yes | No |
| 16481487 | COMPOSITE NANOPARTICLE, PREPARATION METHOD THEREOF AND PREPARATION METHOD OF COMPOSITE NANO PREPARATION USING THEREOF | July 2019 | July 2022 | Abandon | 35 | 2 | 1 | No | No |
| 16519602 | DRIED ATTRACTIVE LURE AND KILL STATIONS FOR THE CONTROL OF AEDES AEGYPTI | July 2019 | December 2020 | Allow | 17 | 0 | 1 | No | No |
| 16518886 | COMPOSITIONS AND METHODS FOR TREATMENT OF PSYCHIATRIC DISORDERS | July 2019 | March 2021 | Abandon | 20 | 0 | 1 | No | No |
| 16505010 | PREVENTING OR TREATING AGENT FOR GLAUCOMA | July 2019 | February 2022 | Abandon | 32 | 3 | 0 | No | No |
| 16456990 | Monovalent Metal Cation Dry Powders | June 2019 | October 2021 | Abandon | 28 | 1 | 0 | No | No |
| 16451488 | ALKALI METAL SALT FOR USE IN TREATMENT OF VARROA DESTRUCTOR MITE INFESTATION OF HONEY BEES | June 2019 | December 2020 | Allow | 18 | 1 | 0 | No | No |
| 16439706 | METHOD TO MODULATE THE SURFACE TENSION OF CANNABIS PLANT MATTER NANOPARTICULATES | June 2019 | February 2021 | Abandon | 20 | 2 | 2 | No | No |
| 16402128 | Transdermal Composition | May 2019 | August 2021 | Abandon | 28 | 3 | 1 | No | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BASQUILL, SEAN M.
With a 24.5% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 13.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BASQUILL, SEAN M works in Art Unit 1613 and has examined 831 patent applications in our dataset. With an allowance rate of 37.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.
Examiner BASQUILL, SEAN M's allowance rate of 37.1% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BASQUILL, SEAN M receive 2.31 office actions before reaching final disposition. This places the examiner in the 61% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by BASQUILL, SEAN M is 32 months. This places the examiner in the 49% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +23.0% benefit to allowance rate for applications examined by BASQUILL, SEAN M. This interview benefit is in the 67% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 13.3% of applications are subsequently allowed. This success rate is in the 10% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 7.6% of cases where such amendments are filed. This entry rate is in the 9% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 40.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 37% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 39.1% of appeals filed. This is in the 7% percentile among all examiners. Of these withdrawals, 41.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 86.7% are granted (fully or in part). This grant rate is in the 87% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.1% of allowed cases (in the 49% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.